Table 4.

Overall summary of treatment-emergent adverse events (safety population; n = 242).

Classification	n(%)
Patients with ≥1 TEAE	158 (65.3)
Patients with ≥1 targeted TEAE	119 (49.2)
Patients with ≥1 serious TEAE	49 (20.2)
Patients with ≥1 serious related TEAE	26 (10.7)
Patients with ≥1 serious targeted TEAE	15 (6.2)
Patients with ≥1 TEAE leading to treatment withdrawal	13 (5.4)
Patients with a fatal TEAE	2 (0.8)

TEAE, treatment-emergent adverse event.